{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:09Z","timestamp":1761512889458,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.eplepsyres.2010.09.004","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T01:45:27Z","timestamp":1287366327000},"page":"170-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy"],"prefix":"10.1016","volume":"92","author":[{"given":"Robert C.","family":"Sergott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Bittman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Christen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1528-1157.1996.tb00627.x","article-title":"Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups","volume":"37","author":"Aicardi","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0010","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0140-6736(05)79254-0","article-title":"Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents","volume":"352","author":"Baulac","year":"1998","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2010.09.004_bib0020","first-page":"S95","article-title":"Vigabatrin","volume":"36","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1014644307518","article-title":"Visual field constriction and electrophysiological changes associated with vigabatrin","volume":"104","author":"Besch","year":"2002","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/seiz.2000.0381","article-title":"Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group","volume":"9","author":"Bruni","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0140-6736(90)90660-W","article-title":"Vigabatrin in infantile spasms","volume":"335","author":"Chiron","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0045","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1167\/iovs.08-3237","article-title":"Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy","volume":"50","author":"Durbin","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0055","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.46.1.54","article-title":"A double-blind, placebo-controlled study of vigabatrin three g\/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort","volume":"46","author":"French","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/seiz.2000.0382","article-title":"Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group","volume":"9","author":"Guberman","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0070","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/bmj.316.7126.232","article-title":"Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients","volume":"316","author":"Harding","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1528-1157.2000.tb00212.x","article-title":"Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication","volume":"41","author":"Hardus","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.55.1.40","article-title":"Visual function loss from vigabatrin: effect of stopping the drug","volume":"55","author":"Johnson","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00023210-200115030-00005","article-title":"Visual field defects with vigabatrin: epidemiology and therapeutic implications","volume":"15","author":"Kalviainen","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0090","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"Kalviainen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0095","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","article-title":"Visual field defects associated with vigabatrin therapy","volume":"67","author":"Lawden","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.eye.6700168","article-title":"Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal","volume":"16","author":"Newman","year":"2002","journal-title":"Eye"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/jnnp.73.3.327","article-title":"The legacy of vigabatrin in a regional epilepsy clinic","volume":"73","author":"Nicolson","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0115","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/jnnp.53.11.1008","article-title":"Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy","volume":"53","author":"Sander","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s004150200041","article-title":"Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study","volume":"249","author":"Schmitz","year":"2002","journal-title":"J. Neurol."},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/01658100903582498","article-title":"Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin","volume":"34","author":"Sergott","year":"2010","journal-title":"Neuro-ophthalmology"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0130","first-page":"185","article-title":"Visual field constriction and anti-epileptic drug treatment","volume":"7","author":"Stefan","year":"2000","journal-title":"Neurol. Psychiat. Brain Res."},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1528-1157.2002.17801.x","article-title":"Visual field constriction in 91 Finnish children treated with vigabatrin","volume":"43","author":"Vanhatalo","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0140","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/11317650-000000000-00000","article-title":"Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study","volume":"23","author":"Wild","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0145","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","article-title":"Characteristics of a unique visual field defect attributed to vigabatrin","volume":"40","author":"Wild","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0150","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","article-title":"Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions","volume":"314","author":"Wilson","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2010.09.004_bib0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-2007-973549","article-title":"Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome","volume":"29","author":"Wohlrab","year":"1998","journal-title":"Neuropediatrics"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121110002445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121110002445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:23:27Z","timestamp":1760275407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121110002445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":31,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0920121110002445"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.09.004","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2010.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}